SCHEMBL30194367

SCHEMBL30194367

CC(=O)c1ccc2cn[nH]c2c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.68
KDM4E B2RXH2 2/20 0.68
ALDH1A1 P00352 2/20 0.68
MAOB P27338 7/20 0.56
DYRK1A Q13627 3/20 0.55
MAP4K4 O95819 1/20 0.55
CLK2 P49760 1/20 0.55
SRPK1 Q96SB4 1/20 0.55
CLK4 Q9HAZ1 1/20 0.55
ROCK2 O75116 1/20 0.51
ROCK1 Q13464 1/20 0.51
NOS1 P29475 3/20 0.50
CYP3A4 P08684 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
HIF1A Q16665 1/20 0.50
PHLPP2 Q6ZVD8 1/20 0.50
HSD17B10 Q99714 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2933207 1.00 MAPT (0.68) MAPTKDM4EALDH1A1MAOBDYRK1A
SCHEMBL29521387 0.86 ROCK2 (0.64) MAPTKDM4EALDH1A1MAOBDYRK1A
SCHEMBL122504 0.86 ROCK2 (0.64) MAPTKDM4EALDH1A1MAOBDYRK1A
SCHEMBL29365815 0.84 ALDH1A1 (0.56) MAPTKDM4EALDH1A1MAOBDYRK1A
SCHEMBL260992 0.84 ALDH1A1 (0.56) MAPTKDM4EALDH1A1MAOBDYRK1A
SCHEMBL21004185 0.83 MAOB (0.52) MAPTKDM4EALDH1A1MAOBDYRK1A
SCHEMBL25436298 0.82 KDM4E (0.50) MAPTKDM4EALDH1A1MAOBDYRK1A
SCHEMBL475069 0.82 AR (0.63) MAPTKDM4EALDH1A1MAOBDYRK1A
Hydrochloric Acid SCHEMBL7001071 0.82 ALDH1A1 (0.55) MAPTKDM4EALDH1A1MAOBDYRK1A
SCHEMBL20187143 0.82 MAOB (0.58) MAPTKDM4EALDH1A1MAOBDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11773102-B2 Heterocyclic compounds as PI3K-γ inhibitors INCYTE CORPORATION (US) 2023-10-03 US disclosed
US-20230009843-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2023-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11773102-B2 Heterocyclic compounds as PI3K-γ inhibitors PIK3CD, PIK3CG, PIK3R5 MAPT 3548/4885KDM4E 3824/4885ALDH1A1 2699/4885
US-20230009843-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS PIK3R5, PIK3CA, PIK3CD MAPT 3639/4885KDM4E 2567/4885ALDH1A1 3638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.